The new range of products is intended to help researchers to tap into the potential of birth tissues to support the development of therapies for various medical conditions
OrganaBio launches new birth tissue products. (Credit: Luma Pimentel on Unsplash)
US-based biotechnology solutions provider OrganaBio has unveiled NeoPAC placenta and umbilical cord tissues to support regenerative medicine and cell therapy.
The new range of products, both Research Use Only (RUO) and clinical (cGMP) grade tissues, is intended to help researchers to tap into the potential of birth tissues to support the development of therapies for various medical conditions.
OrganaBio’s NeoPAC tissues are said to have the potential to treat or prevent a wide range of illnesses like cancers, Graft-versus-host disease (GvHD), haematological disorders, autoimmune diseases, tissue regeneration and neurological disorders.
The biotechnology solutions provider claimed that these tissue offerings give researchers access to a tool that could change patient outcomes and advance the medical industry.
OrganaBio follows Institutional Review Boards (IRB)-approved protocols throughout donor consent and qualification, as well as the tissue collection and processing stages.
This provides researchers with clinically relevant materials for their scientific investigations to advance medical research and patient care.
OrganaBio chief business officer Priya Baraniak said: “The addition of the NeoPAC tissue line to our portfolio of birth tissue-derived cellular starting materials and peripheral blood products allows therapeutics developers more flexibility in working with OrganaBio.
“From donor recruitment and testing to product manufacturing and characterisation, we customise each element to meet each of our customers’ unique needs.
“The launch of the NeoPAC product line further demonstrates our commitment to moving quickly to respond to industry needs around access to high-quality biological materials, and with inherent flexibility built into the product offering.”
The company said that the NeoPAC tissues are collected precisely from healthy donors at the time of birth, from c-section and non-c-section deliveries, via its wholly owned subsidiary, GaiaGift.
Available in both fresh and frozen formats, the researchers have the option to select RUO tissues for preclinical research use or cGMP tissues for clinical applications, depending on the programme’s needs.